Fentanyl and Sudden Death-A Postmortem Perspective for Diagnosing and Predicting Risk

Area of Science:

• Cardiology
• Genetics
• Toxicology

Background:

• Sudden, unexpected deaths pose significant challenges for families, with cardiovascular issues being a primary cause.
• Fentanyl, a synthetic opioid, is increasingly implicated in sudden deaths, often through illicit use and overdose.
• The KCNH2 gene (hERG) plays a crucial role in cardiac electrical activity and is associated with abnormal heart rhythms.

Purpose of the Study:

• To investigate the link between KCNH2 gene variations and sudden death.
• To understand the impact of fentanyl on KCNH2 gene function and cardiac events.
• To explore the utility of genetic testing and counseling for families affected by sudden death.

Main Methods:

• Literature review of scientific studies on KCNH2 gene variations and sudden death.
• Analysis of existing data on fentanyl's role in cardiovascular events and mortality.
• Examination of the potential benefits of genetic testing in identifying predispositions.

Main Results:

• Genetic variations in KCNH2 can predispose individuals to arrhythmias and sudden cardiac death.
• Fentanyl exposure may exacerbate these genetic predispositions, leading to fatal outcomes.
• The co-occurrence of fentanyl use and genetic cardiac vulnerabilities is a growing concern.

Conclusions:

• Genetic testing for KCNH2 variations could identify at-risk individuals and families.
• Understanding the interplay between fentanyl and genetic factors is crucial for preventing sudden deaths.
• Genetic counseling can provide valuable information and support to affected families.